Β-radiating radionuclides in cancer treatment, novel insight into promising approach. (October 2020)

• Record Type: Journal Article
• Authors: Asadian, Samieh; Mirzaei, Hamed; Kalantari, Bagher Aziz; Davarpanah, Mohamad Reza; Mohamadi, Morteza; Shpichka, Anastasia; Nasehi, Leila; Es, Hamidreza Aboulkheyr; Timashev, Peter; Najimi, Mustapha; Gheibi, Nematollah; Hassan, Moustapha; Vosough, Massoud
• Is Part Of: Pharmacological research. Volume 160(2020)
• Publication Date: 2020-10
• Subjects: AURKA activation of aurora A kinase -- E1A adenovirus early region 1A -- Apaf-1 Apoptotic Protease Activating Factor-1 -- BCL-XL B Cell Lymphoma-X L -- BAX BCL (B Cell Lymphoma)-Associated X -- BMF Bcl-2-Modifying Factor -- CEA Carcinoembryonic Antigen -- BNIP3 CL2/adenovirus E1B 19 kDa protein-interacting protein 3 -- CSCs Cancer Stem Cells -- CML Chronic Myelogenous Leukemia -- CDK Cyclin-Dependent Kinase -- CDKN2B cyclin-dependent kinase 4 inhibitor B -- CDK4/6 Cyclin-Dependent Kinase 4/6 -- EBR external beam radiotherapy -- FAS Fas cell surface death receptor -- GEP gastroenteropancreatic -- GADD45 Growth Arrest and DNA-Damage45 -- HCC Hepatocellular Carcinoma -- HER2 Human Epidermal Growth Factor Receptor 2 -- HEDP Hydroxyethylidene Disphosphonate -- KeV Kiloelectron Volt -- plastosome ΔΨm mitochondrial membrane potential -- MAPK8 Mitogen-Activated Protein Kinase 8 -- MYC MYC proto-oncogene -- NET Neuroendocrine Tumor -- PRRT Peptide Receptor Radionuclide Therapy -- PLK polo-like kinase 1 -- PARP Poly (ADP-ribose) Polymerase -- PCNA Proliferating Cell Nuclear Antigen -- RIT radioimmunotherapy -- ROS Reactive Oxygen Species -- r/r-FL Relapsed or Refractory Follicular Lymphoma -- RFWD3 RING finger and WD repeat domain 3 -- SERT Selective Targeted Radionuclide Therapy -- SSRS Somatostatin Receptor Subtypes -- TRT Targeted Radionuclide Therapy -- DMOTP 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylene-phosphonic -- XIAP X-linked Inhibitor of Apoptosis Protein; Apoptosis -- β-radiating radionuclides -- Cancer therapy -- Cell cycle arrest -- Nuclear medicine -- Selective radionuclide therapy; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2020.105070
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Targeted radionuclide therapy, known as molecular radiotherapy is a novel therapeutic module in cancer medicine. β-radiating radionuclides have definite impact on target cells via interference in cell cycle and particular signalings that can lead to tumor regression with minimal off-target effects on the surrounding tissues. Radionuclides play a remarkable role not only in apoptosis induction and cell cycle arrest, but also in the amelioration of other characteristics of cancer cells. Recently, application of novel β-radiating radionuclides in cancer therapy has been emerged as a promising therapeutic modality. Several investigations are ongoing to understand the underlying molecular mechanisms of β-radiating elements in cancer medicine. Based on the radiation dose, exposure time and type of the β-radiating element, different results could be achieved in cancer cells. It has been shown that β-radiating radioisotopes block cancer cell proliferation by inducing apoptosis and cell cycle arrest. However, physical characteristics of the β-radiating element (half-life, tissue penetration range, and maximum energy) and treatment protocol determine whether tumor cells undergo cell cycle arrest, apoptosis or both and to which extent. In this review, we highlighted novel therapeutic effects of β-radiating radionuclides on cancer cells, particularly apoptosis induction and cell cycle arrest.